-
Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial. Ann Oncol. 2026 Oct 24.
Giordano A, Xu B, Yoshinami T, Huang CS, Park YH, Lerzo GL, Li H, Shai A, Jaliffe GG, Itoh M, Williams A, Goel S, Im SA, Cobb P, Golmakani M, Liu F, Moss RA, Vana A, Ignatiadis M, Rugo HS. PMID: 42926110.
View in:
PubMed Mentions:
-
Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study. Ann Oncol. 2026 Oct 24.
Rugo HS, Kok M, Goncalves A, Loirat D, Bianchini G, Fasching PA, Cescon DW, Díaz RR, Zagouri F, Korbenfeld E, Dalenc F, Gilarranz YJ, Hashimoto J, Park YH, Im SA, Hu X, Hirshfield KM, Jia L, Tryfonidis K, Schmid P. PMID: 42926111.
View in:
PubMed Mentions:
-
Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst. 2026 Oct 23.
Margolis S, Kalbasi TR, Zektser Y, Niknafs A, Cui J, Lipsyc-Sharf MD, LeVee AA, Rugo HS, Bardia A, Sedrak MS. PMID: 42920260.
View in:
PubMed Mentions:
-
Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial. JAMA Oncol. 2026 Oct 22.
I-SPY2 Trial Investigators and Advocates, O'Sullivan CC, Kalinsky KM, Yau C, Kulkarni T, Yee D, Wallace AM, Chien AJ, Boughey JC, Elias AD, Nanda R, Isaacs C, Omene C, Stringer-Reasor E, Clark AS, Thomas A, Han HS, Chan N, Williams N, Trivedi MS, Arora M, Vaklavas C, Tseng J, Bommakanti S, Anampa Mesias JD, Zimmer A, Falkson C, Torres ER, Nangia C, Albain KS, Rozenblit M, Zare S, Fazelli S, Chen YY, Huppert LA, Church AL, Beckwith H, Carroll E, Solanki M, Borges VF, Tevis SEA, Chen N, Zeck JC, Kowzun MJ, Sullivan J, Marshall N, Klein ME, Giridhar KV, Acharya-Leon R, Fan B, Walsh EM, Litvak A, Jahan N, McDonald E, Douglas EH, Zena J, Guth A, Johnson K, McGuinness JE, Matsuda K, Shakeri S, Krishnamurthy J, Kang I, Madans A, Feldman S, Johnson M, Katerji H, Ma Y, Matthews JB, Delson AL, LeStage B, Perlmutter J, Petricoin EF, Shatsky RA, Price E, Basu A, Asare AL, Helsten T, McNatt MH, Mukhtar RA, Symmans WF, Borowsky AD, Heshman DL, DeMichele AM, Rugo HS, Hylton NM, van 't Veer LJ, Esserman LJ. PMID: 42911610; PMCID: PMC13691915.
View in:
PubMed Mentions:
-
Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026 Oct 01; 395(13):1285-1298.
Mayer EL, Tolaney SM, Martín M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Pérez-Moreno PD, Rugo HS, evERA Breast Cancer Investigators. PMID: 42814929.
View in:
PubMed Mentions:
-
Development and Validation of a Tool to Measure Documented Health Care Encounter Time. JAMA Netw Open. 2026 Oct 01; 9(10):e2638034.
Chow R, Bayrakdarian S, Gojsevic O, MacMillan E, Balboni T, Bowen J, Bruera E, Chan RJ, Gupta A, Hart NH, Hoskin P, Hui D, Iihara H, Jefford M, Lee SF, Riechelmann R, Rugo HS, Ruhlmann CH, Simone CB, Wong HCY, Zimmermann C, Chung H, Richards GC, Heneghan C, Leigh J, MASCC Emerging Toxicities Study Group. PMID: 42848401; PMCID: PMC13650670.
View in:
PubMed Mentions:
-
ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Ann Surg Oncol. 2026 Oct; 33(11):9659-9660.
Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Van't Veer LJ, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 42536241.
View in:
PubMed Mentions: Fields:
-
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis. Radiother Oncol. 2026 Sep 30; 111800.
Visani L, Becherini C, Kubeczko M, Caini S, Alkner S, Saura C, Starzer AM, Boersma LJ, de Azambuja E, Harbeck N, Stobart H, Spanic T, Coles CE, Cortés J, Curigliano G, Isacke CM, Jackson SP, Jones CM, Kaidar-Person O, Lambertini M, Marangoni E, Morandi A, Offersen B, Paluch-Shimon S, Rugo H, Livi L, Poortmans P, Meattini I, Florence 2026 International Consensus Investigators. PMID: 42815776.
View in:
PubMed Mentions:
-
Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups. ESMO Open. 2026 Oct; 11(10):108549.
Cortes J, Johnston SRD, Martin M, Tolaney SM, Goetz MP, Rugo HS, Sohn J, Ozyilkan O, Abreu MH, Zaiss M, Vianna KM, Nielsen HM, Chan A, Kalofonos H, Morales S, Grimes BR, Amdur S, Neven P. PMID: 42815408; PMCID: PMC13654022.
View in:
PubMed Mentions:
-
Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study. Breast. 2026 Sep 29; 90:104941.
LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic A, Huppert L, Quintal L, Melisko M, Majure M, Chien J, Lechner M, Idossa D, Blaes A, McCann K, Rugo HS, Mortimer J. PMID: 42815081.
View in:
PubMed Mentions:
-
8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines). Breast. 2026 Sep 17; 90:104921.
Cardoso F, Ribeiro JM, Schumacher-Wulf E, Swain SM, Paluch-Shimon S, Penault-Llorca F, Lin NU, Francis PA, Kuper-Hommel M, May A, Hilbers F, Guerrero A, Aapro MS, Azmi R, Bajpai J, Barrios C, Biganzoli L, Boyle F, Caceres V, Carey LA, Chavez-MacGregor M, Cortés J, Dent R, Drury A, El Saghir NS, Elghazaly H, Eniu A, Fallowfield L, Franco Millan SX, Gelmon K, Gilchrist J, Gligorov J, Gradishar WJ, Harbeck N, Hu X, Kaidar-Person O, Kaur R, Kiely B, Kim SB, Nyagabona SK, Lustberg M, Mueller V, Mutebi M, Neciosup S, Ohno S, Pistilli B, Rugo HS, Spanic T, Tsang J, Vuylsteke P, Xu B, Norton L, Winer EP. PMID: 42893682; PMCID: PMC13697336.
View in:
PubMed Mentions:
-
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. Ann Oncol. 2026 Sep 17.
Licata L, Mariani M, Chiavassa A, Partridge AH, Zanibelli C, Jhaveri K, Kalinsky K, Patanè F, Criscitiello C, Lambertini M, Rugo HS, Naldini MM, Notini G, Viale G, Pusztai L, Bianchini G. PMID: 42754095.
View in:
PubMed Mentions:
-
Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review. Eur J Cancer. 2026 Sep 12; 248:117054.
Scotté F, Lustberg M, Aapro M, Ben Abid F, Bošnjak S, Ruhlmann CH, Klastersky J, Mayeur D, Rugo HS, Cooksley T. PMID: 42790204.
View in:
PubMed Mentions:
-
Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Ann Surg Oncol. 2026 Sep 05.
Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 42700336.
View in:
PubMed Mentions:
-
Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention. Support Care Cancer. 2026 Sep 05; 34(10).
Iihara H, Bianchini G, Aapro M, Licata L, Bernareggi A, Navari RM, Park YH, Jordan K, Vidal M, Scotté F, Roeland EJ, Schwartzberg L, Rugo HS. PMID: 42701103; PMCID: PMC13546154.
View in:
PubMed Mentions:
-
Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Ann Surg Oncol. 2026 Sep 03.
Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 42693375.
View in:
PubMed Mentions:
-
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. PMID: 42530945; PMCID: PMC13425239.
View in:
PubMed Mentions: Fields:
-
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE. Clin Cancer Res. 2026 Aug 24.
Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano G, Cortés J, Garcia-Fructuoso I, Aftimos P, Bermejo de Las Heras B, Tolosa P, Yuan Y, Valero V, Lipsyc-Sharf M, Muñoz Romero P, Koraichi Auriol F, Paoli A, Crozier JA, Wasserman T, Kaklamani V. PMID: 42635598.
View in:
PubMed Mentions:
-
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial. Clin Cancer Res. 2026 Aug 14; 32(16):3599-3607.
Jhaveri K, Rugo HS, Cortés J, Oliveira M, Howell SJ, Dalenc F, Gomez HL, Hu X, Krivorotko P, Loibl S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Zhukova L, Nardone A, Wadsworth I, D'Cruz C, Wantenaar T, Das D, de Bruin EC, Turner NC. PMID: 42154572; PMCID: PMC13473863.
View in:
PubMed Mentions: Fields:
-
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Ann Surg Oncol. 2026 Oct; 33(11):9642-9655.
Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 42545411; PMCID: PMC13630848.
View in:
PubMed Mentions: Fields:
-
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future Oncol. 2026 Aug; 22(18):2121-2129.
Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. PMID: 42535874; PMCID: PMC13432852.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy. medRxiv. 2026 Jul 29.
Magbanua MJM, Wolf DM, Yau C, Manon NA, Sayaman RW, Brown Swigart L, Hirst G, Li W, Isaacs C, Shatsky R, Clark AS, Zimmer A, Mukhtar R, Delson AL, Perlmutter J, Pohlmann PR, Hylton NM, Nanda R, Yee D, Symmans WF, Esserman LJ, Rugo HS, DeMichele A, van 't Veer LJ. PMID: 42619946; PMCID: PMC13484324.
View in:
PubMed Mentions:
-
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. ESMO Open. 2026 Aug; 11(8):108330.
Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A, TROPION-Breast01 investigators. PMID: 42497483; PMCID: PMC13449377.
View in:
PubMed Mentions:
-
Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2026 Sep; 26(9):91-100.
Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko M, Majure M, Tsai K, Kordic A, Chien J, Mortimer J, Rugo HS, Lechner MG, Blaes A, McCann KE. PMID: 42607491.
View in:
PubMed Mentions:
-
Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast Cancer Res Treat. 2026 Jul 20; 218(2).
Krasnow NA, Salans M, Jayaraj M, Kuwahara K, Zhou MH, Boreta L, Braunstein SE, Aghi MK, Chien J, Rugo H, Melisko ME, Morshed RA, Vasudevan HN, Huppert LA. PMID: 42474755; PMCID: PMC13385242.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors. Clin Cancer Res. 2026 Jul 17; 32(14):2832-2849.
Poissonnier A, Rugo HS, Horton W, Kim T, DeLuca A, Egeland EV, Cotechini T, Sivagnanam S, Mori M, Yu Y, Park B, Beelen N, Murugan D, Kirchberger N, Kummar S, Mayer IA, Blackwell K, Hwang ES, Coussens LM. PMID: 41894563; PMCID: PMC13376889.
-
Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Cardiooncology. 2026 Jul 10; 12(1).
Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42432812; PMCID: PMC13352844.
View in:
PubMed Mentions:
-
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. ESMO Open. 2026 Jul; 11(7):108243.
Hart L, Rugo HS, Sharma P, Sammons S, Gadi VK, Mavros P, Kaur M, Boualam N, Keane C, Sopher G, Pathak P, Tarantino P. PMID: 42413325; PMCID: PMC13356718.
View in:
PubMed Mentions: Translation:
Humans
-
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Jul; 24(7).
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Leitch AM, Lyons J, McCloskey S, McShane M, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Speers C, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. PMID: 42425164.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Support Care Cancer. 2026 Jun 30; 34(7).
Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Cordoba Mascunano R, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42377594; PMCID: PMC13319156.
View in:
PubMed Mentions: Fields:
-
Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survival. Res Sq. 2026 Jun 30.
Wang Y, Quinones C, Kang I, Rugo H, Martinez E, Seewaldt V, Mortimer J, Nath A, Jones V. PMID: 42427829; PMCID: PMC13345563.
View in:
PubMed Mentions:
-
Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort. Res Sq. 2026 Jun 30.
Jones V, Wang Y, Quinones C, Aljaber D, Nelson E, Nath A, Kang I, Rugo H, Yee L, Seewaldt V, Mortimer J. PMID: 42427842; PMCID: PMC13345549.
View in:
PubMed Mentions:
-
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. NPJ Breast Cancer. 2026 Jun 26.
Rugo HS, Cescon DW, Schmid P, Nowecki Z, Im SA, Md Yusof M, Gallardo C, Iwata H, Lipatov O, Cruz F, Barrios CH, Hegg R, Loi S, Gion M, Otero MT, Árkosy P, Tarnawski R, Yao L, Mejia J, Pan W, Cortés J. PMID: 42362563.
View in:
PubMed Mentions:
-
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. Future Oncol. 2026 Jun; 22(14):1625-1635.
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. PMID: 42324670; PMCID: PMC13367087.
View in:
PubMed Mentions: Fields:
-
Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary. Future Oncol. 2026 Jun; 22(14):1613-1623.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Brufsky A. PMID: 42324685; PMCID: PMC13367080.
View in:
PubMed Mentions: Fields:
-
A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer. J Patient Exp. 2026; 13:23743735261457837.
Beumer A, Carlson M, Arcuri AL, Maues J, Cowden J, Walker S, Shanahan K, Collins JL, Veach AJ, Rugo HS, Burkard ME, Kalinsky KM, Bardia A, Lustberg MB, Papautsky EL, Roberson ML. PMID: 42227000; PMCID: PMC13222401.
View in:
PubMed Mentions:
-
Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Support Care Cancer. 2026 May 29; 34(6).
Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42209784; PMCID: PMC13219080.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey. Clin J Oncol Nurs. 2026 May 18; 30(3):E28-E38.
Ginex PK, Thoele K, Ma Q, Searles Vitko A, Gathirua-Mwangi WG, Liepa AM, Panjic EH, Chou E, Ellis HJ, de Courcy J, Clewes C, Taraba J, Rugo HS. PMID: 42227802; PMCID: PMC13239591.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
QuTILs: Open-Source Image-Based Infiltrating Immune Cell Detection for Research Application. Res Sq. 2026 May 14.
Vater M, Salgado R, Blige E, Lefebvre H, Strahan A, Gatti-Mays M, Rugo H, Ballman K, Watson M, Wen Y, Leon-Ferre R, Niazi K, Symmans WF, Carey L, AbdulJabbar K, Li Z, Stover DG. PMID: 42183372; PMCID: PMC13193113.
View in:
PubMed Mentions:
-
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. Oncologist. 2026 May 08; 31(6).
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS. PMID: 42095602; PMCID: PMC13228134.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer. Support Care Cancer. 2026 May 02; 34(5).
Chow R, Zhang D, Kannout S, Ma A, Zheng C, Blayne A, Dou A, Talwar S, Fazelzad R, Rugo HS, Ruhlmann CH, Iihara H, Affronti ML, Leigh J, Scotté F, Eng L, MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group. PMID: 42068413; PMCID: PMC13135589.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. Adv Ther. 2026 May; 43(5):1855-1868.
Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Rimawi MF, Rugo HS, Tolaney SM, Weiss M, Brufsky A. PMID: 41843049; PMCID: PMC13156212.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort. Mod Pathol. 2026 06; 39(6):101006.
Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. PMID: 42025846.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial. Ann Oncol. 2026 Aug; 37(8):1106-1119.
Juric D, Rugo HS, Reising A, Vervier K, Ma C, Ciruelos EM, Loibl S, Singer CF, Sohn J, Campone M, Conte P, Iwata H, Ghaznawi F, Miller M, Taran T, Su F, André F. PMID: 41967638.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744]. Breast. 2026 Jun; 87:104782.
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS. PMID: 41936467; PMCID: PMC13184477.
View in:
PubMed Mentions: Fields:
-
Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape. Chin Clin Oncol. 2026 Apr; 15(2):26.
Chang HL, Kang IM, Rugo HS. PMID: 42145010.
View in:
PubMed Mentions: Fields:
-
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat. 2026 Mar 30; 217(1).
Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Ji Y, Vidula N, Ellerton J, Smakal M, Zimovjanova M, Weng D. PMID: 41910867; PMCID: PMC13035570.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. Breast. 2026 Jun; 87:104780.
Rugo HS, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Lynce F, Cottu P, Thill M, Curigliano G. PMID: 41950642; PMCID: PMC13090625.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Detection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial mutations in patients with metastatic breast cancer and leptomeningeal disease. Ther Adv Med Oncol. 2026; 18:17588359261424678.
Huppert LA, Fisch S, Her L, Hodgdon C, Brain S, Simmons C, Lai AR, Malevanchik L, Balassanian R, Vasudevan HN, Morshed R, Braunstein S, Boreta L, Majure M, Chien AJ, Rugo HS, Magbanua MJM, Melisko ME. PMID: 41883874; PMCID: PMC13009763.
View in:
PubMed Mentions:
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
Jacob S, Mayer EL, Kacik N, Storniolo AM, Isaacs C, Mayer I, Stearns V, Nanda R, Nangia J, Chien AJ, Moasser M, Melisko M, Wabl C, Muzikansky A, Geradts J, Dillon DA, Park BH, Krop I, Wolff AC, Kochupurakkal B, Shapiro GI, Rugo HS. PMID: 41812623; PMCID: PMC12995829.
View in:
PubMed Mentions: Translation:
HumansCTClinical Trials
-
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. ESMO Open. 2026 Mar; 11(3):106091.
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J. PMID: 41785668; PMCID: PMC12972957.
View in:
PubMed Mentions: Translation:
HumansCTClinical Trials
-
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. Clin Cancer Res. 2026 Mar 02; 32(5):883-893.
Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N, Saji S, Miyoshi Y, Bardia A, Harbeck N, Haiderali A, Fan L, Mejia JA, Karantza V, Llombart-Cussac A. PMID: 41405563.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer. N Engl J Med. 2026 Feb 26; 394(9):918-920.
Rugo HS. PMID: 41740036.
View in:
PubMed Mentions: Fields:
-
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. Breast. 2026 Apr; 86:104744.
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS. PMID: 41830752; PMCID: PMC12996934.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial. Res Sq. 2026 Feb 11.
Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R. PMID: 41727611; PMCID: PMC12919184.
View in:
PubMed Mentions:
-
The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection. Ecancermedicalscience. 2026; 20:2071.
Balch CM, Liao N, Lam DSC, Weitzel JN, Xu RH, Attard G, Bunn PA, Eggermont AMM, He J, Kitagawa Y, Lim ST, Cazap E, Esquivel B, Fan X, Chow LWC, Liu ESF, Said HM, Niederhuber JE, Rubio IT, Zaghloul AS, Arrieta OG, Audisio RA, Beets GL, Coimbra FJF, Gallardo JE, Garber JE, Gronchi A, Heinemann V, Kurian AW, Mutebi M, Mori M, Olopade FI, Rutkowski P, Saleh M, Sanchez WM, Sawaya R, Thompson JF, Tumusiime G, Vallejos CS, Whiteman DC, Wu Y, Yawe KT, Zahrani NAA, Zoras O, Arun BK, Fabian CJ, Gershenwald JE, Gradishar WJ, He J, Kimberg VS, Lam RMK, Lee VHF, Lorusso D, Mok TSK, Perrier ND, Rugo HS, Ulrich C, Are C, Vignat J, Soerjomataram I. PMID: 41877745; PMCID: PMC13006544.
View in:
PubMed Mentions:
-
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. ESMO Open. 2026 Feb; 11(2):105936.
Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, André F, Im SA, Goncalves MD, Lacouture ME, Fasching PA, Leung R. PMID: 41604817; PMCID: PMC12865632.
View in:
PubMed Mentions:
1
-
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data. ESMO Open. 2026 Feb; 11(2):106021.
Tolaney SM, Sammons S, Sandoval-Leon A, Cortes J, Liepa AM, Grimes BR, He D, Cui ZL, Roose J, Gathirua-Mwangi W, Moreira K, O'Shaughnessy J, Neven P, Johnston SRD, Rugo HS. PMID: 41558202; PMCID: PMC12856337.
View in:
PubMed Mentions: Translation:
Humans
-
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399]. Ann Oncol. 2026 Sep; 37(9):1308.
Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. PMID: 41506947.
View in:
PubMed Mentions: Fields:
-
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. Clin Cancer Res. 2026 Jan 06; 32(1):179-187.
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM. PMID: 41235919; PMCID: PMC12770937.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
RISE UP for breast cancer 2024: conference highlights & takeaways. Breast Cancer Res Treat. 2026 Jan 06; 215(2):53.
Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L. PMID: 41493489; PMCID: PMC12774930.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting. JAMA Ophthalmol. 2026 01 01; 144(1):62-68.
Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ. PMID: 41343206; PMCID: PMC12679423.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. Oncologist. 2025 Dec 27; 31(1).
Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS. PMID: 41330717; PMCID: PMC12743619.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol. 2026 May; 37(5):663-674.
Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Rubini Liedke PE, Carroll D, Khan S, Rugo HS, Xu B, Bardia A, TROPION-Breast01 investigators. PMID: 41448362.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun. 2025 Dec 09; 16(1):9945.
Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. PMID: 41365872; PMCID: PMC12690079.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. NPJ Breast Cancer. 2025 Dec 04; 12(1):16.
Iyengar NM, O'Shaughnessy JA, Moore HN, Hamilton E, Jhaveri KL, Ma CX, Tedesco K, Vasekar M, Donahue S, Rugo HS. PMID: 41345397; PMCID: PMC12820357.
View in:
PubMed Mentions:
1
-
Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer. NPJ Breast Cancer. 2025 Dec 03; 11(1):144.
Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa D, Melisko M, Chien AJ, Kim MO, Mortimer J, McCann K, Blaes A, Rugo HS. PMID: 41339346; PMCID: PMC12714743.
View in:
PubMed Mentions:
-
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ Breast Cancer. 2025 Nov 21; 11(1):130.
Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. PMID: 41271741; PMCID: PMC12638943.
View in:
PubMed Mentions:
3
-
Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e100053CX1.
Corti C, Rugo HS, Tolaney SM. PMID: 41270251.
View in:
PubMed Mentions: Fields:
-
Clinical perspective on management of key adverse events with sacituzumab govitecan. Oncologist. 2025 Nov 11; 30(11).
Tolaney SM, Sonpavde GP, Tarantino P, Lustberg MB, Rugo HS. PMID: 41006069; PMCID: PMC12619999.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025. J Natl Compr Canc Netw. 2025 11; 23(11):426-436.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. PMID: 41213254.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study. Breast Cancer Res. 2025 Oct 28; 27(1):191.
Krasnow NA, Jayaraj M, Salans M, Kuwahara K, Zhou MH, Fisch S, Boreta L, Braunstein SE, Aghi MK, Batra-Sharma H, Majure M, Chien J, Rugo HS, Morshed RA, Vasudevan HN, Melisko ME, Huppert LA. PMID: 41153023; PMCID: PMC12570416.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026 02; 37(2):155-165.
Johnston S, Martin M, O'Shaughnessy J, Hegg R, Tolaney SM, Guarneri V, Del Mastro L, Campone M, Sohn J, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Munoz M, San Antonio B, Shahir A, Rastogi P, Harbeck N. PMID: 41110697.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
Improving the quality of life of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (goal 3). Breast. 2025 Dec; 84:104603.
Gelmon K, Villarreal-Garza C, Aubel D, S Rugo H, Maués J, Travado L, Van Meerveld M, C W Chidebe R, Patel B, Attfield G, Lewis A, Cardoso F. PMID: 41298008; PMCID: PMC12683158.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7). Breast. 2025 Dec; 84:104604.
Kiely B, Travado L, Smith AL, Timeus IA, Kim SB, Haidinger R, N M Nanre N, Rugo H, Attfield G, Lewis A, Cardoso F. PMID: 41298009; PMCID: PMC12683155.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. Target Oncol. 2025 Nov; 20(6):917-936.
Finn RS, Rugo HS, Cortes J, Loibl S, Foley G, Gauthier E, Wang Y, Kim S, Anders L, Slamon DJ. PMID: 41087648; PMCID: PMC12669314.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec; 31(12):4205-4213.
Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. PMID: 41062831; PMCID: PMC12705423.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCTClinical Trials
-
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Ann Oncol. 2025 Dec; 36(12):1433-1446.
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025. Electronic address: https://, Panelists of the St. Gallen International Breast Cancer Consensus 2025. PMID: 41072918.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. J Clin Oncol. 2025 Nov 10; 43(32):3547.
Bidard FC, Gessain G, Bachelot T, Frechin L, Vincent-Salomon A, Drubay D, Lemonnier J, Walter T, Penault-Llorca F, Martin AL, Gaudin C, Bichat A, Sassi F, Berlemont S, Chavez-MacGregor M, Rugo HS, Badoual C, Pistilli B, Ribeiro J, Di Meglio A, Lacroix-Triki M, Luis IV, Lerousseau M, André F. PMID: 41056514.
View in:
PubMed Mentions: Fields:
-
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Cancer Res. 2025 Oct 01; 31(19):4040-4048.
Wesolowski R, Rugo HS, Specht JM, Han HS, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. PMID: 40711480; PMCID: PMC12485373.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO Precis Oncol. 2025 Sep; 9:e2500588.
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. PMID: 40893049.
View in:
PubMed Mentions: Fields:
-
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. JNCI Cancer Spectr. 2025 Sep 01; 9(5).
Schettini F, Nucera S, Di Grazia G, Giudici F, Strina C, Milani M, Tancredi R, Conte B, Criscitiello C, Giuliano M, Lambertini M, Sánchez-Bayona R, Pascual T, Arpino G, Del Mastro L, Vigneri P, Cristofanilli M, Rugo HS, Gennari A, Curigliano G, Generali D. PMID: 40796258; PMCID: PMC12413244.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open. 2025 Sep; 10(9):105570.
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. PMID: 40896879; PMCID: PMC12424423.
View in:
PubMed Mentions:
6 Translation:
Humans
-
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Ann Surg Oncol. 2025 Oct; 32(11):8113-8126.
Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R. PMID: 40849380; PMCID: PMC13262329.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. J Clin Oncol. 2025 10; 43(28):3090-3101.
Bidard FC, Gessain G, Bachelot T, Frechin L, Vincent-Salomon A, Drubay D, Lemonnier J, Walter T, Penault-Llorca F, Martin AL, Gaudin C, Bichat A, Sassi F, Berlemont S, Chavez-MacGregor M, Rugo HS, Badoual C, Pistilli B, Ribeiro J, Di Meglio A, Lacroix-Triki M, Vaz Luis I, Lerousseau M, André F. PMID: 40845255; PMCID: PMC12456196.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. Nat Commun. 2025 Aug 20; 16(1):7438.
Williams J, Camarda R, Malkov S, Zimmerman LJ, Manning S, Aran D, Beardsley A, Van de Mark D, Nakagawa R, Chen Y, Berdan C, Louie SM, Mahieu C, Superville D, Winkler J, Willey E, Hutchins EJ, Gagnon JD, Avsaroglu SK, Shinoda K, Gruner M, Nishida H, Ansel KM, Werb Z, Nomura DK, Kajimura S, Butte AJ, Sanders ME, Liebler DC, Rugo HS, Krings G, Shepherd JA, Goga A. PMID: 40835606; PMCID: PMC12368202.
View in:
PubMed Mentions: Fields:
Translation:
HumansAnimalsCells
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.
Navari RM, Tyler T, Inui N, Iihara H, Bonizzoni E, Park YH, Rugo HS, Roeland EJ. PMID: 40782019; PMCID: PMC12407638.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer. 2025 Aug 05; 33(9):756.
Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney S, Treister NS, Matthews C, Johnson M. PMID: 40762824; PMCID: PMC12325563.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Ann Oncol. 2025 11; 36(11):1389-1399.
Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. PMID: 40769277.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Oct; 32(11):8243-8253.
Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. PMID: 40705266; PMCID: PMC12494636.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCTClinical Trials
-
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Oct; 32(11):8211-8219.
Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. PMID: 40699532; PMCID: PMC12494629.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods. NPJ Breast Cancer. 2025 Jul 21; 11(1):75.
Lynce F, Liu X, Li B, McRoy L, Chen C, Liu R, Rugo HS. PMID: 40691446; PMCID: PMC12280009.
View in:
PubMed Mentions:
-
Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates. Int J Radiat Oncol Biol Phys. 2025 11 15; 123(4):1090-1101.
Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. PMID: 40685017.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473384.
LeVee A, Deutsh A, Lindgren ES, Yan R, Moore H, Pasricha ND, Leventhal J, Dent S, Rugo HS. PMID: 40632949.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy. Lancet Oncol. 2025 Jul; 26(7):e332-e333.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. PMID: 40609573.
View in:
PubMed Mentions: Fields:
-
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer. JCO Oncol Pract. 2026 May; 22(5):793-803.
Bardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta A, Kaushik A, Lai C, Shi L, Brufsky A. PMID: 40561376.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast Cancer Res. 2025 Jun 23; 27(1):115.
Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele A, Yee D, van 't Veer L, Rugo H, Symmans WF, Goetz MP, Esserman L, Boughey JC. PMID: 40551254; PMCID: PMC12183850.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
Wolf DM, Yau C, Campbell M, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. PMID: 40526879; PMCID: PMC12184982.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025 Jul; 10(7):105297.
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. PMID: 40532364; PMCID: PMC12212123.
View in:
PubMed Mentions:
-
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. ESMO Open. 2025 Jun; 10(6):105304.
Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, Graff SL. PMID: 40516131; PMCID: PMC12206108.
View in:
PubMed Mentions:
5 Translation:
Humans
-
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109). ESMO Open. 2025 Jun; 10(6):105120.
Naughton MJ, Zahrieh DM, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Meisel JL, Ruiz GM, Loibl S, Isaacs C, Cameron D, Henao-Carrasco FM, Goetz MP, Singer CF, Werutsky G, Rugo HS, Vetter M, Tseng LM, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law EH, Partridge AH, Carey LA, Zoroufy A, Dueck AC, O'Brien P, Hlauschek D, DeMichele A, Mayer EL. PMID: 40472660; PMCID: PMC12173008.
View in:
PubMed Mentions: Translation:
HumansCTClinical Trials
-
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers (Basel). 2025 Jun 04; 17(11).
Rugo HS, Xu B, Dasgupta A, Kaushik A, Verret W, Singh B. PMID: 40507364; PMCID: PMC12153749.
View in:
PubMed Mentions:
-
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis. Clin Cancer Res. 2025 Jun 03; 31(11):2196-2209.
Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. PMID: 40100138; PMCID: PMC12130808.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCells
-
Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e100053.
Corti C, Rugo HS, Tolaney SM. PMID: 40367401.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. Adv Ther. 2025 Jul; 42(7):2973-2987.
Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Patt D, Rimawi M, Rugo H, Tolaney SM, Weiss M, Brufsky A. PMID: 40354012; PMCID: PMC12182450.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 08; 30(5).
Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. PMID: 40349139; PMCID: PMC12065936.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast. 2025 Aug; 82:104485.
Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. PMID: 40344957; PMCID: PMC12138406.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clin Cancer Res. 2025 May 01; 31(9):1625-1635.
Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G. PMID: 40019493; PMCID: PMC12010963.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025 Apr 15; 11(1):34.
Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. PMID: 40234477; PMCID: PMC12000457.
View in:
PubMed Mentions:
19
-
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO Precis Oncol. 2025 Apr; 9:e2400742.
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. PMID: 40209141; PMCID: PMC12005863.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer. Cancer Med. 2025 Apr; 14(7):e70719.
Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. PMID: 40145289; PMCID: PMC11947744.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary. Future Oncol. 2025 May; 21(11):1287-1295.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. PMID: 40159782; PMCID: PMC12051525.
View in:
PubMed Mentions: Fields:
-
Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer. J Clin Oncol. 2025 Jun 20; 43(18):2137-2138.
Bardia A, Pistilli B, Rugo H. PMID: 40153734.
View in:
PubMed Mentions:
1 Fields:
-
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy. Ann Oncol. 2025 Jul; 36(7):832-837.
Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F. PMID: 40139460.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol. 2025 Apr; 21(10):1261-1272.
Park YH, Bianchini G, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS. PMID: 40105595; PMCID: PMC11988240.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial. ESMO Open. 2025 Apr; 10(4):104497.
Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, Kim S, Ma J, Gauthier E, Broughton E, Doan J, Rugo HS. PMID: 40107156; PMCID: PMC11964640.
View in:
PubMed Mentions:
2 Translation:
HumansCTClinical Trials
-
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. Curr Oncol. 2025 Mar 15; 32(3).
Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. PMID: 40136373; PMCID: PMC11941552.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Ther Adv Med Oncol. 2025; 17:17588359251320285.
Gluz O, Xu B, Nanda R, Dasgupta A, Kaushik A, Verret W, Sharma A, Singh B, Rugo HS. PMID: 40093981; PMCID: PMC11907608.
View in:
PubMed Mentions:
1
-
Redefining clinical trial strategic design to support drug approval in medical oncology. Ann Oncol. 2025 Jun; 36(6):645-650.
Antonarelli G, Pérez-García JM, Gion M, Rugo H, Schmid P, Bardia A, Hurvitz S, Harbeck N, Tolaney SM, Curigliano G, Llombart-Cussac A, Cortés J. PMID: 40086733.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist. 2025 03 10; 30(3).
Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, Graff SL, Rugo HS. PMID: 40139260; PMCID: PMC11942793.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative). Future Oncol. 2025 Mar; 21(7):775-786.
Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. PMID: 40045471; PMCID: PMC11916373.
View in:
PubMed Mentions: Fields:
-
Management of toxicities from antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Mar-Apr; 23(2):96-99.
Rugo HS. PMID: 40153670.
View in:
PubMed Mentions:
1 Fields:
-
Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey. Support Care Cancer. 2025 Jan 07; 33(2):76.
Lai-Kwon J, Rutherford C, Best S, Rugo HS, Ruhlmann CH, Jefford M. PMID: 39775113.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025 Jan; 10(1):104103.
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. PMID: 39754979; PMCID: PMC11758200.
View in:
PubMed Mentions:
20 Translation:
Humans
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 12 06; 29(12):1032-1043.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Rugo HS. PMID: 39418346; PMCID: PMC11630750.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
Rugo HS, Campbell M, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 39625569; PMCID: PMC11785665.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol. 2025 02; 36(2):172-184.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS. PMID: 39477071; PMCID: PMC12252650.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clin Breast Cancer. 2025 Jan; 25(1):1-11.
Moore HN, Goncalves MD, Johnston AM, Mayer EL, Rugo HS, Gradishar WJ, Zylla DM, Bergenstal RM. PMID: 39462728.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2025 Jan; 209(1):147-159.
Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. PMID: 39305392; PMCID: PMC11785630.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer. Future Oncol. 2024; 20(37):2901-2913.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Park YH, Sohn JH, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin E, Grinsted L, Schiavon G, Foxley A, Rugo HS. PMID: 39283299; PMCID: PMC11575593.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277672; PMCID: PMC12089997.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277671; PMCID: PMC12044543.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. NPJ Breast Cancer. 2024 Sep 12; 10(1):79.
Im SA, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, Takano T, Huang CS, Chung CF, Tsugawa K, Park YH, Matsumoto K, Inoue K, Kwong A, Loi S, Fu W, Pan W, Karantza V, Rugo HS, Schmid P. PMID: 39266535; PMCID: PMC11393332.
View in:
PubMed Mentions:
12
-
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025 01 20; 43(3):285-296.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B, TROPION-Breast01 Investigators. PMID: 39265124; PMCID: PMC11771365.
View in:
PubMed Mentions:
74 Fields:
Translation:
HumansCTClinical Trials
-
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Oncologist. 2024 09 06; 29(9):768-779.
Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. PMID: 38748596; PMCID: PMC11379636.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024 Sep; 9(9):103697.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. PMID: 39241495; PMCID: PMC11406080.
View in:
PubMed Mentions:
6 Translation:
HumansCTClinical Trials
-
Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes. J Clin Invest. 2024 09 03; 134(17).
Winkler J, Tan W, Diadhiou CM, McGinnis CS, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee JV, Hinrichs JH, Wagner PS, Singh N, Hein MY, Borja M, Detweiler AM, Liu SY, Nanjaraj A, Sitarama V, Rugo HS, Neff N, Gartner ZJ, Oliveira Pisco A, Goga A, Darmanis S, Werb Z. PMID: 39225101; PMCID: PMC11364385.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansAnimalsCells
-
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2024 09; 25(9):1231-1244.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group. PMID: 39214106.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. NPJ Breast Cancer. 2024 Aug 21; 10(1):75.
Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, Loi S, Vater M, Glover K, Watson M, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, Rugo HS. PMID: 39169033; PMCID: PMC11339397.
View in:
PubMed Mentions:
5
-
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2371.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. PMID: 38914862; PMCID: PMC11333270.
View in:
PubMed Mentions:
1 Fields:
-
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer. 2024 Oct 01; 130(19):3251-3271.
Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. PMID: 38985794.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jul 09; 10(1):55.
Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38982075; PMCID: PMC11233646.
View in:
PubMed Mentions:
-
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 07; 22(5):331-357.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. PMID: 39019058.
View in:
PubMed Mentions:
280 Fields:
Translation:
Humans
-
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer. 2024 Jun 29; 10(1):54.
Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y. PMID: 38951507; PMCID: PMC11217366.
View in:
PubMed Mentions:
2
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators. PMID: 38935923; PMCID: PMC11527383.
View in:
PubMed Mentions:
29 Fields:
Translation:
HumansCTClinical Trials
-
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024; 20(31):2343-2355.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. PMID: 38922307; PMCID: PMC11520537.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. J Clin Oncol. 2024 08 01; 42(22):2680-2690.
Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, Neven P, Kanagavel D, Cohen P, Paux G, Cartot-Cotton S, Stefanova-Urena M, Deyme L, Aouni J, Sebastien B, Bardia A. PMID: 38889373.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study. Breast Cancer Res Treat. 2024 Aug; 206(3):625-636.
Huppert LA, Fisch S, Tsopurashvili E, Somepalle SS, Salans M, Vasudevan HN, Jo Chien A, Majure M, Rugo HS, Balassanian R, Boreta L, Melisko ME. PMID: 38888796; PMCID: PMC11208257.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jun 06; 10(1):41.
Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 38844800; PMCID: PMC11156627.
View in:
PubMed Mentions:
-
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open. 2024 Jun; 9(6):103466.
Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. PMID: 38838498; PMCID: PMC11190462.
View in:
PubMed Mentions:
9 Translation:
HumansCTClinical Trials
-
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 38470545; PMCID: PMC11147708.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 06 03; 65(6):938-943.
Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. PMID: 38697672; PMCID: PMC11149593.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 08; 30(8):2242-2250.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. PMID: 38824244; PMCID: PMC11333285.
View in:
PubMed Mentions:
24 Fields:
Translation:
HumansCTClinical Trials
-
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024 Aug; 76:103756.
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Chavez-MacGregor M, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim SB, Koppikar S, Kuper-Hommel MJJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. PMID: 38896983; PMCID: PMC11231614.
View in:
PubMed Mentions:
90 Fields:
Translation:
Humans
-
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. J Natl Cancer Inst. 2024 05 08; 116(5):717-727.
Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J. PMID: 38070159.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer. 2024 Apr 26; 10(1):34.
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J. PMID: 38671001; PMCID: PMC11053007.
View in:
PubMed Mentions:
13
-
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Apr 25; 10(1):33.
Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38664404; PMCID: PMC11045722.
View in:
PubMed Mentions:
32
-
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs). Curr Ophthalmol Rep. 2024 Jun; 12(2):13-22.
Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND. PMID: 38756824; PMCID: PMC11095972.
View in:
PubMed Mentions:
8
-
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Res. 2024 03 04; 26(1):36.
Rodón J, Demanse D, Rugo HS, Burris HA, Simó R, Farooki A, Wellons MF, André F, Hu H, Vuina D, Quadt C, Juric D. PMID: 38439079; PMCID: PMC10913434.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 05 20; 42(15):1738-1744.
Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. PMID: 38422473; PMCID: PMC11107894.
View in:
PubMed Mentions:
77 Fields:
Translation:
HumansCTClinical Trials
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. PMID: 38109213; PMCID: PMC10956403.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024 03; 25(3):317-325.
Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, O'Shaughnessy JA, Johnston S, Brufsky A, Tilley WD, Overmoyer B. PMID: 38342115.
View in:
PubMed Mentions:
21 Fields:
Translation:
HumansCTClinical Trials
-
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(3):509-520.
Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. PMID: 38194132; PMCID: PMC10959837.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res Treat. 2024 Apr; 204(2):249-259.
Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE. PMID: 38123789; PMCID: PMC10948526.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2024 06; 195:110060.
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. PMID: 38122852.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2023; 15:17588359231216095.
Jhaveri K, O'Shaughnessy J, Fasching PA, Tolaney SM, Yardley DA, Sharma VK, Biswas C, Thuerigen A, Pathak P, Rugo HS. PMID: 38107828; PMCID: PMC10722948.
View in:
PubMed Mentions:
8
-
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312.
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. PMID: 38086377; PMCID: PMC10772394.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023 12; 34(12):1141-1151.
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. PMID: 38072514.
View in:
PubMed Mentions:
21 Fields:
Translation:
HumansCTClinical Trials
-
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. Int J Cancer. 2024 02 15; 154(4):701-711.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. PMID: 37831416.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Jan; 203(2):197-204.
Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS. PMID: 37815684; PMCID: PMC10787873.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023; 13:1237751.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. PMID: 37841423; PMCID: PMC10569486.
View in:
PubMed Mentions:
16
-
Clinical course of multiple sclerosis and patient experiences during breast cancer treatment. Mult Scler. 2023 07; 29(8):967-978.
Nylander AN, Singh J, Poole S, Anderson A, Marrie RA, Rugo H, Bove R. PMID: 37291903; PMCID: PMC10338705.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 06; 21(6):594-608.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. PMID: 37308117.
View in:
PubMed Mentions:
232 Fields:
Translation:
Humans
-
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 08; 19(8):539-546.
Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. PMID: 37207306; PMCID: PMC10424906.
View in:
PubMed Mentions:
36 Fields:
Translation:
Humans
-
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 37146605; PMCID: PMC10330514.
View in:
PubMed Mentions:
98 Fields:
Translation:
Humans
-
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. NPJ Breast Cancer. 2023 Apr 07; 9(1):22.
Im KW, Huppert LA, Malevanchik L, Rugo HS, Combes AJ, Campbell MJ, Krummel MF, Melisko ME. PMID: 37029150; PMCID: PMC10082042.
View in:
PubMed Mentions:
3
-
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023 Sep-Oct; 73(5):480-515.
Huppert LA, Gumusay O, Idossa D, Rugo HS. PMID: 36939293.
View in:
PubMed Mentions:
98 Fields:
Translation:
Humans
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2023 Feb; 67:94-101.
Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. PMID: 36702070; PMCID: PMC9982309.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128.
Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 36456573; PMCID: PMC9715670.
View in:
PubMed Mentions:
12
-
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022 Nov 21; 13(1):7140.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. PMID: 36414627; PMCID: PMC9681724.
View in:
PubMed Mentions: Fields:
-
Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633.
Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
View in:
PubMed Mentions: Fields:
Translation:
HumansCells
-
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023 Jan; 197(1):137-148.
Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ. PMID: 36319907.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7750.
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35798896.
View in:
PubMed Mentions: Fields:
-
Little Downside. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114(4):573.
Singer L, Rugo HS. PMID: 36244389.
View in:
PubMed Mentions: Fields:
-
First, do no harm: risk of secondary cancer after breast cancer treatment. Lancet Oncol. 2022 11; 23(11):1350-1352.
Rugo HS, Singer L. PMID: 36240804.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7739-7747.
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35810223; PMCID: PMC9550696.
View in:
PubMed Mentions:
13 Fields:
Translation:
Humans
-
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022 06 27; 13(1):3671.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. PMID: 35760778; PMCID: PMC9237085.
View in:
PubMed Mentions:
43 Fields:
Translation:
HumansAnimalsCells
-
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. PMID: 35623341; PMCID: PMC9426306.
View in:
PubMed Mentions:
181 Fields:
Translation:
Humans
-
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406.
Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium. PMID: 35513244.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality. JAMA Oncol. 2022 02 01; 8(2):203-204.
DeBoer RJ, Rugo HS, Shulman LN. PMID: 34882172.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. PMID: 34741023; PMCID: PMC8571284.
View in:
PubMed Mentions:
47 Fields:
Translation:
Humans
-
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. PMID: 34529000; PMCID: PMC8446908.
View in:
PubMed Mentions:
58 Fields:
Translation:
Humans
-
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139.
Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. PMID: 34697300; PMCID: PMC8547221.
View in:
PubMed Mentions:
6
-
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131.
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 34611148; PMCID: PMC8492731.
View in:
PubMed Mentions:
21
-
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 34143979; PMCID: PMC11064785.
View in:
PubMed Mentions:
196 Fields:
Translation:
HumansCTClinical Trials
-
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021 May; 187(1):155-165.
Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. PMID: 33591468; PMCID: PMC8062601.
View in:
PubMed Mentions:
17 Fields:
Translation:
HumansCTClinical Trials
-
A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial. Glob Adv Health Med. 2020; 9:2164956120964712.
Dhruva A, Wu C, Miaskowski C, Hartogensis W, Rugo HS, Adler SR, Kaptchuk TJ, Kelkar R, Agarawal S, Vadodaria A, Garris E, Hecht FM. PMID: 33312762; PMCID: PMC7716077.
View in:
PubMed Mentions:
6
-
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 01; 71(1):34-46.
Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807; PMCID: PMC7537198.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansPHPublic Health
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. PMID: 32701140; PMCID: PMC7378873.
View in:
PubMed Mentions:
114 Fields:
Translation:
Humans
-
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584.
Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091; PMCID: PMC7367885.
View in:
PubMed Mentions:
104 Fields:
Translation:
HumansCellsCTClinical Trials
-
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020 09; 31(9):1223-1230.
Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A, CONTROL Study Investigators. PMID: 32464281.
View in:
PubMed Mentions:
56 Fields:
Translation:
HumansCTClinical Trials
-
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137; PMCID: PMC7058271.
View in:
PubMed Mentions:
398 Fields:
Translation:
HumansCTClinical Trials
-
Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Res Treat. 2020 May; 181(1):23-29.
Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H. PMID: 32240457.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Rep. 2020 03 10; 30(10):3368-3382.e7.
Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A. PMID: 32160543; PMCID: PMC7085414.
View in:
PubMed Mentions:
37 Fields:
Translation:
HumansAnimalsCells
-
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. JAMA Surg. 2020 03 01; 155(3):e195410.
Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31913413; PMCID: PMC6990971.
View in:
PubMed Mentions:
76 Fields:
Translation:
HumansCTClinical Trials
-
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 05; 31(5):582-589.
Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. PMID: 32178964.
View in:
PubMed Mentions:
47 Fields:
Translation:
HumansCTClinical Trials
-
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, Translational Breast Cancer Research Consortium (TBCRC). PMID: 32070401; PMCID: PMC7027068.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCellsCTClinical Trials
-
Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. J Clin Oncol. 2020 04 01; 38(10):1070-1080.
Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, Rugo HS. PMID: 32058846; PMCID: PMC7106981.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment. Breast J. 2020 07; 26(7):1472-1474.
Franc BL, Thombley R, Luo Y, John Boscardin W, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31960541; PMCID: PMC7369243.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193.
Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. PMID: 32014370.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 01; 18(1):12-22.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. PMID: 31910384.
View in:
PubMed Mentions:
51 Fields:
Translation:
Humans
-
Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer. Technol Cancer Res Treat. 2020 Jan-Dec; 19:1533033819896331.
Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP. PMID: 32129154; PMCID: PMC7057408.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019; 5:47.
Vidula N, Yau C, Wolf D, Rugo HS. PMID: 31840050; PMCID: PMC6904475.
View in:
PubMed Mentions:
22
-
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452.
Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. PMID: 31802506; PMCID: PMC7064382.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators. PMID: 31786121.
View in:
PubMed Mentions:
660 Fields:
Translation:
HumansCTClinical Trials
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. PMID: 31772121.
View in:
PubMed Mentions:
22 Fields:
Translation:
Humans
-
Identifying tests related to breast cancer care in claims data. Breast J. 2020 06; 26(6):1227-1230.
Franc BL, Thombley R, Luo Y, Boscardin WJ, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31736191; PMCID: PMC7304302.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Treatment of early-stage hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Nov; 17(11):596-599.
Rugo HS. PMID: 31851159.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. PMID: 32043771; PMCID: PMC7011632.
View in:
PubMed Mentions:
37 Fields:
Translation:
Humans
-
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol. 2020 02; 46(2):223-228.
Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, Rugo HS, Wolmark N, Ansell P, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31606288.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 10; 17(10):555-558.
Rugo HS. PMID: 31730581.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020 01 01; 26(1):110-121.
Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. PMID: 31527167.
View in:
PubMed Mentions:
111 Fields:
Translation:
Humans
-
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin Breast Cancer. 2020 04; 20(2):e173-e180.
Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V. PMID: 31836434.
View in:
PubMed Mentions:
22 Fields:
Translation:
HumansCTClinical Trials
-
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Sep; 17(9):486-489.
Rugo HS. PMID: 31549968.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. PMID: 31250880.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2020 03; 26(3):368-375.
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. PMID: 31448513; PMCID: PMC7155112.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260.
Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C, Breast Cancer Therapy Expert Group (BCTEG). PMID: 32139271.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Achieving Improved Survival Outcomes in Advanced Breast Cancer. N Engl J Med. 2019 07 25; 381(4):371-372.
Rugo HS. PMID: 31340099.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019; 11:1758835919854238.
Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS. PMID: 31258629; PMCID: PMC6589951.
View in:
PubMed Mentions:
88
-
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019 12; 24(12):1514-1525.
Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. PMID: 31217344; PMCID: PMC6975938.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019; 5:17.
Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. PMID: 31240240; PMCID: PMC6570645.
View in:
PubMed Mentions:
14
-
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019 Sep; 177(2):401-408.
Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. PMID: 31172405.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 05 16; 380(20):1929-1940.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, SOLAR-1 Study Group. PMID: 31091374.
View in:
PubMed Mentions:
1321 Fields:
Translation:
HumansCTClinical Trials
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncol. 2019 Jul; 15(19):2211-2225.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J. PMID: 31074641; PMCID: PMC7466911.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. PMID: 31004299.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCTClinical Trials
-
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Med. 2019 05; 8(5):2064-2073.
Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V. PMID: 30968588; PMCID: PMC6536946.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications. Plast Reconstr Surg Glob Open. 2019 Apr; 7(4):e2188.
Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR. PMID: 31321184; PMCID: PMC6554181.
View in:
PubMed Mentions:
6
-
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 30939096; PMCID: PMC7587424.
View in:
PubMed Mentions:
133 Fields:
Translation:
HumansCTClinical Trials
-
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):419-430.
Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. PMID: 30032196; PMCID: PMC6449170.
View in:
PubMed Mentions:
51 Fields:
Translation:
HumansCTClinical Trials
-
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):397-404.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. PMID: 30475950.
View in:
PubMed Mentions:
457 Fields:
Translation:
HumansCTClinical Trials
-
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):405-411.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. PMID: 30475947.
View in:
PubMed Mentions:
369 Fields:
Translation:
HumansCTClinical Trials
-
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. PMID: 30786188.
View in:
PubMed Mentions:
436 Fields:
Translation:
HumansCTClinical Trials
-
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. PMID: 32031889; PMCID: PMC7106976.
View in:
PubMed Mentions:
67 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126.
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. PMID: 30787125.
View in:
PubMed Mentions:
101 Fields:
Translation:
Humans
-
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019 02 01; 5(2):e184475.
Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. PMID: 30543347; PMCID: PMC6439561.
View in:
PubMed Mentions:
143 Fields:
Translation:
HumansCTClinical Trials
-
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019 May; 175(1):5-15.
Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. PMID: 30671765; PMCID: PMC6491395.
View in:
PubMed Mentions:
42 Fields:
Translation:
Humans
-
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 Apr; 174(3):719-729.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. PMID: 30632023; PMCID: PMC6438948.
View in:
PubMed Mentions:
226 Fields:
Translation:
HumansCTClinical Trials
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. PMID: 30593513.
View in:
PubMed Mentions:
58 Fields:
Translation:
Humans
-
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 05 01; 25(9):2717-2724.
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group. PMID: 30563931.
View in:
PubMed Mentions:
71 Fields:
Translation:
HumansCTClinical Trials
-
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 02 01; 37(4):318-327.
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. PMID: 30557521.
View in:
PubMed Mentions:
567 Fields:
Translation:
HumansCellsCTClinical Trials
-
Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2019 Mar; 15(7):777-790.
Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G. PMID: 30500264.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. PMID: 30260474; PMCID: PMC6379108.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease. Am J Clin Oncol. 2018 Nov; 41(11):1037-1042.
Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean M, Boscardin WJ, Rugo HS, Dudley RA. PMID: 32463216.
View in:
PubMed Mentions:
3 Fields:
-
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018 11; 104:160-168.
Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. PMID: 30359909.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCellsCTClinical Trials
-
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators. PMID: 30345906.
View in:
PubMed Mentions:
2302 Fields:
Translation:
HumansCTClinical Trials
-
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31.
Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. PMID: 30211312; PMCID: PMC6125436.
View in:
PubMed Mentions:
22
-
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 09 01; 29(9):1939-1947.
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. PMID: 30124753.
View in:
PubMed Mentions:
84 Fields:
Translation:
HumansCTClinical Trials
-
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. Am J Cancer Res. 2018; 8(9):1873-1886.
Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X. PMID: 30323979; PMCID: PMC6176180.
View in:
PubMed Mentions:
8
-
Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. Am J Hosp Palliat Care. 2019 Feb; 36(2):143-146.
Rabow MW, McGowan M, Small R, Keyssar R, Rugo HS. PMID: 30153741.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. PMID: 30110579; PMCID: PMC10600918.
View in:
PubMed Mentions:
1088 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018 12; 18(6):489-497.
Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. PMID: 30153978.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. Clin Adv Hematol Oncol. 2018 Aug; 16(8):533-537.
Rugo HS. PMID: 30148824.
View in:
PubMed Mentions: Fields:
-
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 08 01; 29(8):1634-1657.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. PMID: 30032243; PMCID: PMC7360146.
View in:
PubMed Mentions:
529 Fields:
Translation:
Humans
-
Circulating Tumors Cells as a Biomarker of Radiation Benefit. JAMA Oncol. 2018 08 01; 4(8):e180194.
Speers C, Rugo HS. PMID: 29800965.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al. Ann Oncol. 2018 08 01; 29(8):1878.
Rugo HS, Iyer S, Huang C. PMID: 29873677.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 Sep; 101:123-133.
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. PMID: 30053671.
View in:
PubMed Mentions:
42 Fields:
Translation:
Humans
-
The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. Future Oncol. 2018 Oct; 14(24):2461-2469.
Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS. PMID: 30001151.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. J Natl Compr Canc Netw. 2018 07; 16(7):829-837.
Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA. PMID: 30006425.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. PMID: 29871907; PMCID: PMC6168379.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCells
-
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018 Jun; 30(3):315-326.
Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. PMID: 30046226; PMCID: PMC6037585.
View in:
PubMed Mentions:
15
-
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018 Aug; 170(3):547-557.
O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. PMID: 29675680.
View in:
PubMed Mentions:
26 Fields:
Translation:
HumansCTClinical Trials
-
The new world of biosimilars in oncology: Translation of data to the clinic. Eur J Cancer. 2018 06; 96:125-127.
Rugo HS, Cortes J. PMID: 29680363.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clin Cancer Res. 2018 07 15; 24(14):3348-3357.
Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA. PMID: 29618616.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCells
-
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018 04 01; 29(4):888-894.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. PMID: 29360932; PMCID: PMC5913649.
View in:
PubMed Mentions:
90 Fields:
Translation:
HumansCTClinical Trials
-
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2804-2811.
Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. PMID: 29559561.
View in:
PubMed Mentions:
224 Fields:
Translation:
HumansCellsCTClinical Trials
-
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 03; 29(3):271-280.
Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. PMID: 29360661; PMCID: PMC5821476.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 04; 19(4):497-509.
Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. PMID: 29501363.
View in:
PubMed Mentions:
371 Fields:
Translation:
HumansCTClinical Trials
-
Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc. 2018 04; 149(4):291-298.
Chambers MS, Rugo HS, Litton JK, Meiller TF. PMID: 29439772.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018 05 01; 36(13):1291-1299.
Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. PMID: 29401002; PMCID: PMC5920739.
View in:
PubMed Mentions:
231 Fields:
Translation:
HumansCTClinical Trials
-
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7.
Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. PMID: 29352368; PMCID: PMC5882621.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018 01 08; 33(1):60-74.e6.
de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. PMID: 29316433; PMCID: PMC5764109.
View in:
PubMed Mentions:
230 Fields:
Translation:
HumansAnimalsCells
-
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499.
Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. PMID: 29311117; PMCID: PMC5856614.
View in:
PubMed Mentions:
28 Fields:
Translation:
HumansCells
-
Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Rev Anticancer Ther. 2018 01; 18(1):3-18.
Vidula N, Rugo HS. PMID: 29192520.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCells
-
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. PMID: 29223990.
View in:
PubMed Mentions:
82 Fields:
Translation:
HumansCells
-
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 12 01; 28(12):3111.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28327998; PMCID: PMC5834023.
View in:
PubMed Mentions:
52 Fields:
-
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20; 35(36):4035-4041.
Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. PMID: 29095678.
View in:
PubMed Mentions:
281 Fields:
Translation:
HumansCTClinical Trials
-
Real-world use of scalp cooling to reduce chemotherapy-related hair loss. Clin Adv Hematol Oncol. 2017 Nov; 15(11):828-831.
Rugo HS. PMID: 29200414.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 11; 166(1):327-328.
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28884461; PMCID: PMC6828475.
View in:
PubMed Mentions:
1 Fields:
-
Dual HER2 Blockade. Breast Care (Basel). 2017 Oct; 12(5):345-349.
Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M. PMID: 29234257; PMCID: PMC5704717.
View in:
PubMed Mentions:
-
The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):703-708.
Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H. PMID: 29086230.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Use of Neoadjuvant Platinum-The Ongoing Conundrum. JAMA Oncol. 2017 10 01; 3(10):1312-1314.
Rugo HS, Gelmon K. PMID: 28715579.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2018 01; 167(1):117-122.
Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME. PMID: 28921303.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansAnimalsCTClinical Trials
-
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31.
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. PMID: 28948212; PMCID: PMC5572474.
View in:
PubMed Mentions:
56
-
Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541.
Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. PMID: 28811315.
View in:
PubMed Mentions:
29 Fields:
Translation:
HumansCells
-
Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Breast Cancer. 2018 02; 18(1):19-28.
Rugo HS, Voigt J. PMID: 28939291.
View in:
PubMed Mentions:
30 Fields:
Translation:
Humans
-
Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? J Clin Oncol. 2017 09 20; 35(27):3089-3091.
Chien AJ, Rugo HS. PMID: 28783451.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161.
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28660429.
View in:
PubMed Mentions:
1 Fields:
-
Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2017 Aug; 15(8):607-614.
Rugo HS. PMID: 28949948.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply. JAMA Oncol. 2017 08 01; 3(8):1142.
Melisko ME, Hwang J, Rugo HS. PMID: 28727874.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Aug 01; 3(8):1043-1050.
Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. PMID: 28208174; PMCID: PMC5553624.
View in:
PubMed Mentions:
66 Fields:
Translation:
HumansCTClinical Trials
-
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Res Treat. 2017 Oct; 165(3):601-609.
Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J. PMID: 28681171; PMCID: PMC5709225.
View in:
PubMed Mentions:
19 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 07; 15(7):883-893.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. PMID: 28687576.
View in:
PubMed Mentions:
95 Fields:
Translation:
Humans
-
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423.
Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. PMID: 28620884; PMCID: PMC5711539.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Sep; 165(2):329-341.
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28612225; PMCID: PMC5543189.
View in:
PubMed Mentions:
23 Fields:
-
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138.
Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. PMID: 28577080; PMCID: PMC5725604.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCTClinical Trials
-
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5218-5224.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. PMID: 28533223; PMCID: PMC5581697.
View in:
PubMed Mentions:
361 Fields:
Translation:
HumansCTClinical Trials
-
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159.
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28503722.
View in:
PubMed Mentions:
32 Fields:
Translation:
HumansCTClinical Trials
-
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. PMID: 28489510.
View in:
PubMed Mentions:
249 Fields:
Translation:
HumansCTClinical Trials
-
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017 05; 76:205-215.
Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS. PMID: 28360015.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 06; 163(3):535-544.
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. PMID: 28324268; PMCID: PMC5448790.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662.
Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. PMID: 28314691.
View in:
PubMed Mentions:
93 Fields:
Translation:
HumansCTClinical Trials
-
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 07 08; 67(4):290-303.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. PMID: 28294295.
View in:
PubMed Mentions:
460 Fields:
Translation:
Humans
-
Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast. 2017 Jun; 33:76-82.
Rugo HS, Rossi G, Rizzi G, Aapro M. PMID: 28285236.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat. 2017 Jun; 163(2):199-205.
Rugo HS, Melin SA, Voigt J. PMID: 28275922; PMCID: PMC5410200.
View in:
PubMed Mentions:
37 Fields:
Translation:
Humans
-
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319.
Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. PMID: 27832260.
View in:
PubMed Mentions:
42 Fields:
Translation:
HumansCTClinical Trials
-
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614.
Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. PMID: 28196257; PMCID: PMC5639721.
View in:
PubMed Mentions:
59 Fields:
Translation:
Humans
-
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. Breast. 2017 04; 32:269-270.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28109648.
View in:
PubMed Mentions: Fields:
-
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2017 01 03; 317(1):37-47.
Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng ML, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Ray S, Yanez Ruiz EP, Pennella E, Heritage Study Investigators. PMID: 27918780.
View in:
PubMed Mentions:
70 Fields:
Translation:
HumansCTClinical Trials
-
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 01 01; 28(1):16-33.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28177437; PMCID: PMC5378224.
View in:
PubMed Mentions:
199 Fields:
Translation:
Humans
-
Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Adv Exp Med Biol. 2017; 1026:403-418.
Rugo HS, Li H, Gui X. PMID: 29282695.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017 Feb; 31:244-259.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 27927580.
View in:
PubMed Mentions:
91 Fields:
Translation:
Humans
-
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. Curr Opin Support Palliat Care. 2016 12; 10(4):336-342.
Dawood S, Rugo HS. PMID: 27755140.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017 04; 25(4):1127-1135.
Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. PMID: 27885469; PMCID: PMC5321708.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 11 17; 375(20):1925-1936.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. PMID: 27959613.
View in:
PubMed Mentions:
1458 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Netw. 2016 11; 14(11):1357-1370.
VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. PMID: 27799507.
View in:
PubMed Mentions:
49 Fields:
Translation:
Humans
-
When to Treat, With What, and for How Long: That Is the Question! J Oncol Pract. 2016 11; 12(11):1160-1162.
Dawood S, Rugo HS. PMID: 27858543.
View in:
PubMed Mentions: Fields:
-
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 11; 22(11):1321-1329.
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PMID: 27775705; PMCID: PMC5341692.
View in:
PubMed Mentions:
102 Fields:
Translation:
HumansAnimalsCells
-
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus. 2016; 5(1):1033.
Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J. PMID: 27441152; PMCID: PMC4938835.
View in:
PubMed Mentions:
4
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. PMID: 27406347; PMCID: PMC5259561.
View in:
PubMed Mentions:
264 Fields:
Translation:
HumansCTClinical Trials
-
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist. 2016 10; 21(10):1165-1175.
Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS. PMID: 27368881; PMCID: PMC5061543.
View in:
PubMed Mentions:
114 Fields:
Translation:
HumansCTClinical Trials
-
Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2016 Jul; 14(7):494-7.
Rugo HS. PMID: 27379943.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 08; 5(8):1897-907.
Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. PMID: 27334013; PMCID: PMC4971919.
View in:
PubMed Mentions:
25 Fields:
Translation:
Humans
-
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016 Jun 21; 7(25):38359-38366.
Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS. PMID: 27224917; PMCID: PMC5122395.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103.
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. PMID: 27217461.
View in:
PubMed Mentions:
305 Fields:
Translation:
Humans
-
Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. J Clin Oncol. 2016 07 01; 34(19):2203-5.
Wolff AC, Rugo HS. PMID: 27185850.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. PMID: 27138575; PMCID: PMC5012690.
View in:
PubMed Mentions:
55 Fields:
Translation:
HumansCTClinical Trials
-
A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 2016 May; 46:73-9.
Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. PMID: 27135548.
View in:
PubMed Mentions:
23 Fields:
Translation:
Humans
-
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
View in:
PubMed Mentions:
22 Fields:
Translation:
HumansCTClinical Trials
-
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 26868124.
View in:
PubMed Mentions:
13 Fields:
Translation:
Humans
-
HER2-positive breast cancer: is more treatment better? Lancet Oncol. 2016 Mar; 17(3):268-270.
Rugo HS, Chien AJ. PMID: 26874902.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016 Mar; 27(3):519-25.
Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R. PMID: 26759276; PMCID: PMC4769991.
View in:
PubMed Mentions:
41 Fields:
Translation:
Humans
-
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. PMID: 26539793; PMCID: PMC5654518.
View in:
PubMed Mentions:
51 Fields:
Translation:
Humans
-
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book. 2016; 35:e40-54.
Rugo HS, Vidula N, Ma C. PMID: 27249746.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015 Nov; 7(6):321-39.
Jiang H, Rugo HS. PMID: 26557900; PMCID: PMC4622301.
View in:
PubMed Mentions:
19
-
Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49.
Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. PMID: 26520840.
View in:
PubMed Mentions:
39 Fields:
Translation:
HumansCells
-
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016 Feb 10; 34(5):419-26.
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. PMID: 26503204; PMCID: PMC5070556.
View in:
PubMed Mentions:
130 Fields:
Translation:
Humans
-
A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166.
Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. PMID: 26496203; PMCID: PMC4619669.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCells
-
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Nov; 16(15):1556-1568.
Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. PMID: 26482278.
View in:
PubMed Mentions:
37 Fields:
Translation:
HumansCTClinical Trials
-
Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. Clin Breast Cancer. 2016 Feb; 16(1):18-22.
Rugo HS. PMID: 26507507.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:651879.
Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. PMID: 26421300; PMCID: PMC4573229.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug; 13(8):1012-39.
Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C, National comprehensive cancer network. PMID: 26285247; PMCID: PMC5499710.
View in:
PubMed Mentions:
431 Fields:
Translation:
Humans
-
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb; 16(1):8-17.
Vidula N, Rugo HS. PMID: 26303211.
View in:
PubMed Mentions:
45 Fields:
Translation:
Humans
-
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.
Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. PMID: 26208485.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. PMID: 26211600; PMCID: PMC5365030.
View in:
PubMed Mentions:
58 Fields:
Translation:
Humans
-
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res. 2015; 7:175-88.
Palli SR, Grabner M, Quimbo RA, Rugo HS. PMID: 26124681; PMCID: PMC4476437.
View in:
PubMed Mentions:
6
-
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9.
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. PMID: 26056183; PMCID: PMC4500830.
View in:
PubMed Mentions:
118 Fields:
Translation:
HumansCTClinical Trials
-
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73.
Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ. PMID: 26021444; PMCID: PMC4479083.
View in:
PubMed Mentions:
53 Fields:
Translation:
HumansCells
-
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. PMID: 25981899; PMCID: PMC5057177.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. PMID: 25847936; PMCID: PMC4451173.
View in:
PubMed Mentions:
208 Fields:
Translation:
HumansCTClinical Trials
-
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):605-11.
Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ. PMID: 25833209.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium (TBCRC). PMID: 25779953; PMCID: PMC6186432.
View in:
PubMed Mentions:
46 Fields:
Translation:
HumansCTClinical Trials
-
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 25757412; PMCID: PMC4457605.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14.
Schwartzberg LS, Rugo HS, Aapro MS. PMID: 25856052.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. PMID: 25712686; PMCID: PMC4490043.
View in:
PubMed Mentions:
47 Fields:
Translation:
Humans
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 25564897; PMCID: PMC4313867.
View in:
PubMed Mentions:
304 Fields:
Translation:
HumansCTClinical Trials
-
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat. 2015 Jan; 149(2):439-48.
Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA. PMID: 25552364.
View in:
PubMed Mentions:
17 Fields:
Translation:
HumansCTClinical Trials
-
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 01; 33(4):340-8.
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. PMID: 25534386; PMCID: PMC4302215.
View in:
PubMed Mentions:
64 Fields:
Translation:
Humans
-
Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105.
Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium. PMID: 25524311.
View in:
PubMed Mentions:
27 Fields:
Translation:
HumansCells
-
SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2015 Mar 15; 121(6):893-9.
Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. PMID: 25469673.
View in:
PubMed Mentions:
36 Fields:
Translation:
Humans
-
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. Clin Ther. 2015 Jan 01; 37(1):134-44.
Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H. PMID: 25433768.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2015 Apr 01; 21(7):1511-3.
Vidula N, Rugo HS. PMID: 25351747.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCells
-
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 01; 32(34):3840-7.
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. PMID: 25349301.
View in:
PubMed Mentions:
131 Fields:
Translation:
HumansCTClinical Trials
-
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014 Nov 10; 26(5):623-37.
Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. PMID: 25446896; PMCID: PMC4254570.
View in:
PubMed Mentions:
600 Fields:
Translation:
HumansAnimalsCells
-
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat. 2014 Nov; 148(1):99-106.
Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. PMID: 25257727; PMCID: PMC8374454.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct; 23(5):489-502.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E, European School of Oncology, European Society of Medical Oncology. PMID: 25244983.
View in:
PubMed Mentions:
137 Fields:
Translation:
Humans
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014 Oct; 25(10):1871-1888.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. PMID: 25234545; PMCID: PMC4176456.
View in:
PubMed Mentions:
145 Fields:
Translation:
Humans
-
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014 Dec; 25(12):2357-2362.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. PMID: 25231953; PMCID: PMC6267855.
View in:
PubMed Mentions:
264 Fields:
Translation:
HumansCTClinical Trials
-
Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. Clin Breast Cancer. 2015 Feb; 15(1):43-7.
Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D, Fowble B. PMID: 25245425.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. PMID: 25144817; PMCID: PMC4162656.
View in:
PubMed Mentions:
39 Fields:
Translation:
HumansCTClinical Trials
-
Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond. Ann Oncol. 2014 Oct; 25(10):2096-2098.
Rugo HS, Aapro M. PMID: 25085504.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. Clin Adv Hematol Oncol. 2014 Aug; 12(8 Suppl 15):3-21; quiz 22.
Gradishar WJ, Twelves C, Rugo HS. PMID: 25768893.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Hormone therapy in premenopausal women with early-stage breast cancer. N Engl J Med. 2014 Jul 10; 371(2):175-6.
Rugo HS. PMID: 25006724.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. PMID: 25030168; PMCID: PMC4487551.
View in:
PubMed Mentions:
351 Fields:
Translation:
HumansAnimalsCells
-
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Sep 01; 120(17):2657-64.
Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. PMID: 24930388; PMCID: PMC4232097.
View in:
PubMed Mentions:
34 Fields:
Translation:
Humans
-
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. PMID: 24888816; PMCID: PMC4076026.
View in:
PubMed Mentions:
111 Fields:
Translation:
Humans
-
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014 May 02; 14:307.
Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. PMID: 24885258; PMCID: PMC4011780.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64.
Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. PMID: 24743708; PMCID: PMC4037822.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549; PMCID: PMC4017711.
View in:
PubMed Mentions:
22 Fields:
Translation:
HumansCTClinical Trials
-
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34.
Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. PMID: 24706168; PMCID: PMC4031392.
View in:
PubMed Mentions:
45 Fields:
Translation:
Humans
-
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. 2014 Apr; 25(4):808-815.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA. PMID: 24615500; PMCID: PMC3969554.
View in:
PubMed Mentions:
53 Fields:
Translation:
Humans
-
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014 Jul; 25(7):1328-1333.
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. PMID: 24603643; PMCID: PMC4071754.
View in:
PubMed Mentions:
116 Fields:
Translation:
HumansCTClinical Trials
-
Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15.
Morrow GR, Navari RM, Rugo HS. PMID: 24874107.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Management of chemotherapy-induced nausea and vomiting in clinical practice. Clin Adv Hematol Oncol. 2014 Mar; 12 Suppl 9(3):9-11.
Rugo HS. PMID: 25855943.
View in:
PubMed Mentions:
1 Fields:
-
Informational needs of patients with metastatic breast cancer: what questions do they ask, and are physicians answering them? J Cancer Educ. 2014 Mar; 29(1):175-80.
Danesh M, Belkora J, Volz S, Rugo HS. PMID: 24142513.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer. Indian J Cancer. 2014 Jan-Mar; 51(1):73-9.
Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda R, Pavitran K, Mehta A, Parmar V, Desai S, Nair R, Doval D. PMID: 24947101.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . J Natl Compr Canc Netw. 2014 Jan; 12(1):82-126.
Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB, Bergman MA, Sundar H. PMID: 24453295.
View in:
PubMed Mentions:
61 Fields:
Translation:
Humans
-
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014 Feb; 143(3):459-67.
Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. PMID: 24362951; PMCID: PMC3907668.
View in:
PubMed Mentions:
45 Fields:
Translation:
Humans
-
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013 Dec; 13(6):421-432.e8.
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. PMID: 24267730.
View in:
PubMed Mentions:
54 Fields:
Translation:
HumansCTClinical Trials
-
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct; 30(10):870-84.
Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. PMID: 24158787; PMCID: PMC3898123.
View in:
PubMed Mentions:
245 Fields:
Translation:
HumansCTClinical Trials
-
Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90.
Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M, National comprehensive cancer network. PMID: 24142827.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70.
Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. PMID: 24062208; PMCID: PMC3824350.
View in:
PubMed Mentions:
24 Fields:
Translation:
Humans
-
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Nov; 29(11):1463-73.
Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. PMID: 23962028.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 01; 19(19):5505-12.
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research Consortium (TBCRC 011). PMID: 23965901; PMCID: PMC4086643.
View in:
PubMed Mentions:
356 Fields:
Translation:
HumansCTClinical Trials
-
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013 Aug; 49(12):2621-32.
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. PMID: 23735704.
View in:
PubMed Mentions:
25 Fields:
Translation:
Humans
-
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3693-702.
André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. PMID: 23658459.
-
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. PMID: 23652380; PMCID: PMC3662840.
View in:
PubMed Mentions:
34 Fields:
Translation:
HumansCTClinical Trials
-
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):411-9.
Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. PMID: 23649189; PMCID: PMC3669514.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 May 15; 119(10):1908-15.
Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. PMID: 23504821.
View in:
PubMed Mentions:
42 Fields:
Translation:
HumansCTClinical Trials
-
Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.
DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. PMID: 23470967; PMCID: PMC4096560.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. PMID: 23444220.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCTClinical Trials
-
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013 May 01; 105(9):654-63.
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. PMID: 23425564; PMCID: PMC6430494.
View in:
PubMed Mentions:
46 Fields:
Translation:
HumansCTClinical Trials
-
Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18.
Grunberg SM, Slusher B, Rugo HS. PMID: 23598819.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCells
-
New developments in metastatic breast cancer: general discussion. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):16-7.
Vahdat LT, Rugo HS, Perez EA. PMID: 24765684.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
New developments in metastatic breast cancer: integrating recent data into clinical practice. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):1-18; quiz 19.
Perez EA, Rugo HS, Vahdat LT. PMID: 24892840.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
New developments in metastatic breast cancer: introduction. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):4-7.
Rugo HS. PMID: 24637554.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst. 2013 Jan 16; 105(2):104-12.
Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC. PMID: 23264681; PMCID: PMC3611850.
View in:
PubMed Mentions:
52 Fields:
Translation:
Humans
-
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. PMID: 23169510.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12.
Chien AJ, Rugo HS. PMID: 23143215; PMCID: PMC3528960.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
View in:
PubMed Mentions:
38 Fields:
Translation:
HumansCells
-
Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol. 2012 Nov; 8(11):1383-96.
Keck S, Glencer AC, Rugo HS. PMID: 23148612.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansAnimalsCells
-
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012 Oct 01; 14(5):R129.
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU. PMID: 23025714; PMCID: PMC4053106.
View in:
PubMed Mentions:
72 Fields:
Translation:
Humans
-
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol. 2012 Oct 01; 30(28):3444-7.
Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. PMID: 22927522; PMCID: PMC6076005.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83.
Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA. PMID: 22923238; PMCID: PMC3439611.
View in:
PubMed Mentions:
19 Fields:
Translation:
Humans
-
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012 Oct; 70(4):591-601.
Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. PMID: 22886072.
View in:
PubMed Mentions:
42 Fields:
Translation:
HumansCTClinical Trials
-
The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35.
Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. PMID: 22798157.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 Sep; 6(3):324-32.
Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. PMID: 22752834.
View in:
PubMed Mentions:
43 Fields:
Translation:
Humans
-
Reversing hormone resistance: have we found the golden key? J Clin Oncol. 2012 Aug 01; 30(22):2707-9.
Rugo HS, Keck S. PMID: 22753913.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012 Oct; 29(7):807-19.
Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. PMID: 22692561.
View in:
PubMed Mentions:
23 Fields:
Translation:
Humans
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. PMID: 22689807.
View in:
PubMed Mentions:
235 Fields:
Translation:
HumansCTClinical Trials
-
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23.
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. PMID: 22665533; PMCID: PMC3413275.
View in:
PubMed Mentions:
273 Fields:
Translation:
HumansCellsCTClinical Trials
-
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. PMID: 22649152; PMCID: PMC3434983.
View in:
PubMed Mentions:
223 Fields:
Translation:
Humans
-
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 Sep 10; 30(26):3234-41.
Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. PMID: 22649126.
View in:
PubMed Mentions:
147 Fields:
Translation:
HumansCTClinical Trials
-
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul; 2(7):638-51.
Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z. PMID: 22728437; PMCID: PMC3546490.
View in:
PubMed Mentions:
48 Fields:
Translation:
HumansAnimalsCells
-
Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012 May; 13(5):425-37.
McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, Elboim C, Abrams G, Hamolsky D, Dunn L, Rugo H, Dodd M, Paul SM, Neuhaus J, Cooper B, Schmidt B, Langford D, Cataldo J, Aouizerat BE. PMID: 22515947; PMCID: PMC3348353.
View in:
PubMed Mentions:
57 Fields:
Translation:
Humans
-
Antiemesis. J Natl Compr Canc Netw. 2012 Apr; 10(4):456-85.
Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG, National Comprehensive Cancer Network. PMID: 22491046.
View in:
PubMed Mentions:
25 Fields:
Translation:
Humans
-
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52.
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. PMID: 22425534.
View in:
PubMed Mentions:
111 Fields:
Translation:
Humans
-
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012 Jun; 133(3):1067-75.
Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. PMID: 22415477.
View in:
PubMed Mentions:
64 Fields:
Translation:
Humans
-
Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012 Mar 20; 30(9):898-901.
Rugo HS. PMID: 22331930.
View in:
PubMed Mentions:
18 Fields:
Translation:
Humans
-
Senior adult oncology. J Natl Compr Canc Netw. 2012 Feb; 10(2):162-209.
Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. PMID: 22308515; PMCID: PMC3656650.
View in:
PubMed Mentions:
42 Fields:
Translation:
Humans
-
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer. 2012 Sep 01; 118(17):4098-104.
Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. PMID: 22281842.
View in:
PubMed Mentions:
16 Fields:
Translation:
HumansCTClinical Trials
-
Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. Oncology (Williston Park). 2012 Jan; 26(1):26, 28-9.
Rugo HS. PMID: 22393793.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012 Apr; 132(3):1107-18.
Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. PMID: 22207277; PMCID: PMC3335925.
View in:
PubMed Mentions:
67 Fields:
Translation:
Humans
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators. PMID: 22198468; PMCID: PMC3332388.
View in:
PubMed Mentions:
197 Fields:
Translation:
Humans
-
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20.
Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. PMID: 22198412; PMCID: PMC3397213.
View in:
PubMed Mentions:
26 Fields:
Translation:
HumansCTClinical Trials
-
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011 Dec 15; 25(24):2559-72.
Shiao SL, Ganesan AP, Rugo HS, Coussens LM. PMID: 22190457; PMCID: PMC3248678.
View in:
PubMed Mentions:
175 Fields:
Translation:
HumansAnimals
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 09; 366(6):520-9.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. PMID: 22149876; PMCID: PMC5705195.
View in:
PubMed Mentions:
1324 Fields:
Translation:
HumansCTClinical Trials
-
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11):1-16.
Rugo HS, O'Shaughnessy JA, Perez EA. PMID: 22355830.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11 Suppl 25):1-16.
Rugo HS, O'Shaughnessy JA, Perez EA. PMID: 22362269.
View in:
PubMed Mentions: Fields:
Translation:
HumansAnimals
-
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93.
Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. PMID: 21990397.
View in:
PubMed Mentions:
181 Fields:
Translation:
HumansCTClinical Trials
-
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 2011 Oct 04; 3(10):64.
Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. PMID: 21970596; PMCID: PMC3239226.
View in:
PubMed Mentions:
7 Fields:
-
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6897-904.
Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. PMID: 21903773.
View in:
PubMed Mentions:
54 Fields:
Translation:
HumansCTClinical Trials
-
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801.
Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. PMID: 21825174; PMCID: PMC3287000.
View in:
PubMed Mentions:
272 Fields:
Translation:
HumansCells
-
New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 20):1-15.
Perez EA, Mooberry S, Twelves C, Rugo HS. PMID: 22362034.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA. 2011 Jul 20; 306(3):312-4.
Rugo HS, Rosen MP. PMID: 21771995.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43.
Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. PMID: 21768129.
View in:
PubMed Mentions:
198 Fields:
Translation:
Humans
-
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun; 1(1):54-67.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. PMID: 22039576; PMCID: PMC3203524.
View in:
PubMed Mentions:
1002 Fields:
Translation:
HumansAnimalsCells
-
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35.
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. PMID: 21559012; PMCID: PMC3111195.
View in:
PubMed Mentions:
188 Fields:
Translation:
HumansCellsCTClinical Trials
-
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011 Jun 20; 29(18):2459-65.
Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. PMID: 21555686.
View in:
PubMed Mentions:
55 Fields:
Translation:
HumansCTClinical Trials
-
Systemic treatment of early breast cancer--a biological perspective. J Surg Oncol. 2011 May 01; 103(6):619-26.
Greenberg S, Stopeck A, Rugo HS. PMID: 21480257.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407.
McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. PMID: 21350003; PMCID: PMC4994894.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. PMID: 21224365; PMCID: PMC3023787.
View in:
PubMed Mentions:
52 Fields:
Translation:
Humans
-
Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer. Breast Dis. 2011; 33(2):83-92.
Li J, Rugo HS. PMID: 22142661.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCells
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 01; 29(4):398-405.
Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. PMID: 21172893.
View in:
PubMed Mentions:
288 Fields:
Translation:
HumansCTClinical Trials
-
Cost comparison of capecitabine in patients with breast cancer. Am J Clin Oncol. 2010 Dec; 33(6):550-6.
Rugo HS, Kohles J, Schulman KL. PMID: 20051811.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw. 2010 Dec; 8(12):1331-9.
Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. PMID: 21147900.
View in:
PubMed Mentions:
31 Fields:
Translation:
Humans
-
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):421-39.
Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. PMID: 21147685.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010 Sep; 10 Suppl 2:S20-9.
Greenberg S, Rugo HS. PMID: 20805062.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010 Aug 01; 10(4):288-93.
Rugo H, Brammer M, Zhang F, Lalla D. PMID: 20705561.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug; 8(8):904-31.
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. PMID: 20870636.
View in:
PubMed Mentions:
115 Fields:
Translation:
Humans
-
Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv. 2010 Sep; 4(3):247-55.
Melisko ME, Goldman M, Rugo HS. PMID: 20602189; PMCID: PMC2921487.
View in:
PubMed Mentions:
13 Fields:
Translation:
Humans
-
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev. 2011 Apr; 37(2):97-104.
Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M, Coleman R. PMID: 20594763.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46.
Chien AJ, Rugo HS. PMID: 20175700.
View in:
PubMed Mentions:
23 Fields:
Translation:
HumansAnimals
-
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. PMID: 20124187.
View in:
PubMed Mentions:
377 Fields:
Translation:
HumansCTClinical Trials
-
Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010 Jan-Feb; 16(1):33-8.
Greenberg S, Rugo HS. PMID: 20164688.
View in:
PubMed Mentions:
31 Fields:
Translation:
Humans
-
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 01; 28(1):77-82.
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. PMID: 19901117; PMCID: PMC2799234.
View in:
PubMed Mentions:
60 Fields:
Translation:
Humans
-
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. PMID: 19901120; PMCID: PMC3664032.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study. Patient Educ Couns. 2009 Dec; 77(3):360-8.
Belkora JK, Loth MK, Volz S, Rugo HS. PMID: 19850438.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 01; 28(4):628-33.
Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. PMID: 19841327; PMCID: PMC3940895.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20.
Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. PMID: 19801324.
View in:
PubMed Mentions:
43 Fields:
Translation:
HumansPHPublic Health
-
Antiemesis. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):572-95.
Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S. PMID: 19460282.
View in:
PubMed Mentions:
13 Fields:
Translation:
Humans
-
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer. 2009 Apr 28; 9:127.
Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. PMID: 19400938; PMCID: PMC2684746.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 01; 27(16):2630-7.
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. PMID: 19380449.
View in:
PubMed Mentions:
247 Fields:
Translation:
HumansCellsCTClinical Trials
-
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48.
Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS. PMID: 19294387.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treat Res. 2009; 151:197-215.
Jo Chien A, Rugo HS. PMID: 19593514.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCells
-
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83.
Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. PMID: 19047117; PMCID: PMC2748748.
View in:
PubMed Mentions:
56 Fields:
Translation:
HumansCTClinical Trials
-
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol. 2009 Jan; 6(1):25-33.
Melisko ME, Glantz M, Rugo HS. PMID: 18936791.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol. 2008 Jul; 9(7):602-3.
Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. PMID: 18598923.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9.
Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. PMID: 18543100.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol. 2008 Jul; 88(3):359-65.
Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. PMID: 18398574.
View in:
PubMed Mentions:
34 Fields:
Translation:
Humans
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. PMID: 18347007.
View in:
PubMed Mentions:
193 Fields:
Translation:
HumansCTClinical Trials
-
Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7.
Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. PMID: 18501057.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
The importance of distant metastases in hormone-sensitive breast cancer. Breast. 2008 Jan; 17 Suppl 1:S3-8.
Rugo HS. PMID: 18279764.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008 Jan; 19(1):16-27.
Rugo HS. PMID: 17693420.
View in:
PubMed Mentions:
29 Fields:
Translation:
Humans
-
Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007 Aug; 88(8):1002-8.
Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. PMID: 17678662.
View in:
PubMed Mentions:
56 Fields:
Translation:
Humans
-
Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. Oncol Nurs Forum. 2007 Jul; 34(4):813-20.
Dibble SL, Luce J, Cooper BA, Israel J, Cohen M, Nussey B, Rugo H. PMID: 17723973.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S21-8.
Rugo HS. PMID: 17683650.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Hormonal therapy for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):273-91.
Rugo HS. PMID: 17512449.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):303-19.
Traina TA, Rugo HS, Dickler M. PMID: 17512451.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb; 8(1):47-60.
Lin A, Rugo HS. PMID: 17660958.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28.
Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. PMID: 17111207.
-
The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2.
Sledge GW, Rugo HS, Burstein HJ. PMID: 17139244.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92.
Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. PMID: 16770540.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansAnimalsCells
-
Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. PMID: 16503501.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs. 2005 Sep; 8(9):739-54.
Man M, Rugo H. PMID: 16118697.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansAnimals
-
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73.
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. PMID: 16027440.
View in:
PubMed Mentions:
70 Fields:
Translation:
HumansCTClinical Trials
-
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20; 23(24):5474-83.
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. PMID: 16027439.
View in:
PubMed Mentions:
167 Fields:
Translation:
HumansCTClinical Trials
-
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81.
Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. PMID: 15908529.
View in:
PubMed Mentions:
109 Fields:
Translation:
Humans
-
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54.
Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. PMID: 15899072.
View in:
PubMed Mentions:
30 Fields:
Translation:
Humans
-
High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7.
Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. PMID: 15803005.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. PMID: 15681523.
View in:
PubMed Mentions:
361 Fields:
Translation:
HumansCTClinical Trials
-
Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004 Dec; 199(6):856-62.
Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. PMID: 15555967.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemother Pharmacol. 2004 Jun; 53(6):468-74.
Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. PMID: 15138711.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004; 9 Suppl 1:43-9.
Rugo HS. PMID: 15178815.
View in:
PubMed Mentions:
25 Fields:
Translation:
HumansAnimals
-
The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003 Dec; 30(6):749-62.
Rugo HS, Ahles T. PMID: 14663776.
View in:
PubMed Mentions:
20 Fields:
Translation:
Humans
-
Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol. 2003 Apr; 4(2):165-73.
Rugo HS. PMID: 12594943.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Ocular manifestations of leukemia: leukemic infiltration versus infectious process. Ophthalmology. 2001 Dec; 108(12):2293-300.
Gordon KB, Rugo HS, Duncan JL, Irvine AR, Howes EL, O'Brien JM, Carter SR. PMID: 11733273.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001 Sep 01; 19(17):3771-9.
Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. PMID: 11533101.
View in:
PubMed Mentions:
41 Fields:
Translation:
HumansCellsCTClinical Trials
-
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59.
Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. PMID: 11456056.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park). 2000 Nov; 14(11A):151-61.
Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C, National Comprehensive Cancer Network. PMID: 11195408.
View in:
PubMed Mentions:
149 Fields:
Translation:
Humans
-
High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. PMID: 10967563.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients. Bone Marrow Transplant. 2000 Jan; 25(2):153-60.
Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, Berenson JR. PMID: 10673673.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCellsCTClinical Trials
-
Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000; 6(1):50-7.
Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolfe JL. PMID: 10707999.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999 Mar 15; 93(6):1858-68.
Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. PMID: 10068658.
View in:
PubMed Mentions:
14 Fields:
Translation:
HumansCellsCTClinical Trials
-
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. PMID: 9827814.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997 Apr; 11(4):485-9.
Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC, Beer M, Ahmed T. PMID: 9096687.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997 Feb; 15(2):833-9.
Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. PMID: 9053511.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy. 1996 Oct; 28(8):680-5.
Terdiman JP, Linker CA, Ries CA, Damon LE, Rugo HS, Ostroff JW. PMID: 8934085.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
Bone marrow transplantation retinopathy in the absence of radiation therapy. Am J Ophthalmol. 1996 Aug; 122(2):268-70.
Cunningham ET, Irvine AR, Rugo HS. PMID: 8694100.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transplant. 1996 Jan; 17(1):93-9.
Damon LE, Rugo HS, Ries CA, Linker CA. PMID: 8673063.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia. 1994 Apr; 8(4):535-41.
Damon LE, Rugo HS, Ries CA, Linker CA. PMID: 8152248.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11.
Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA. PMID: 7535460.
View in:
PubMed Mentions: Fields:
Translation:
HumansCells
-
Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49.
Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL. PMID: 8342075.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8.
Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. PMID: 8422457.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest. 1992 Mar; 89(3):1032-9.
Rugo HS, O'Hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M, O'Garra A. PMID: 1541664; PMCID: PMC442953.
View in:
PubMed Mentions:
22 Fields:
Translation:
AnimalsCells
-
Frequency and organization of papA homologous DNA sequences among uropathogenic digalactoside-binding Escherichia coli strains. Infect Immun. 1991 Jun; 59(6):2089-96.
Denich K, Craiu A, Rugo H, Muralidhar G, O'Hanley P. PMID: 2037369; PMCID: PMC257970.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCells
-
Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol. 1990; 2(9):821-32.
O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, Barbis D, Stall A, Cupp J, Moore K, et al. PMID: 1703785.
View in:
PubMed Mentions:
98 Fields:
Translation:
AnimalsCells
-
Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 1989 Dec; 87(6):605-13.
O'Hanley P, Easaw J, Rugo H, Easaw S. PMID: 2589395.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans